Clinical Trial Phases

Planning for Drug-Device Combination Studies in Early Phase Trials

Posted on digi By digi

With the rise of biologics, injectables, inhalers, wearable delivery systems, and on-body injectors, drug-device combination products are reshaping how therapies are administered. In early-phase trials, particularly Phase 1, these combinations pose unique challenges. Both the drug and the device must be evaluated for safety, usability, and compatibility—often under compressed timelines. This tutorial explores how to plan, design, and execute early-phase studies involving drug-device combinations with a focus on human factors, regulatory compliance, and integrated clinical endpoints.
Click to read the full article.

Phase 1 (Safety and Dosage)

Real-Time Pharmacovigilance Through Social Media Monitoring in Phase 4 Trials

Posted on digi By digi

Modern pharmacovigilance extends beyond hospitals, registries, and electronic health records. In today’s digital age, patients share experiences in real time through social media platforms, health forums, and online communities. For sponsors conducting Phase 4 clinical trials, these platforms represent a vast, untapped resource for real-time adverse event detection, sentiment analysis, and drug safety monitoring.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

How to Create a Risk-Based Monitoring Plan (RBMP) for Phase 3 Trials: A Step-by-Step Guide

Posted on digi By digi

Phase 3 clinical trials are often global, complex, and resource-intensive. Traditional 100% Source Data Verification (SDV) across all sites is no longer sustainable—either financially or logistically. That’s why modern regulatory guidance encourages the use of Risk-Based Monitoring (RBM)—an approach that focuses resources where risks are highest.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Blinding and Randomization Considerations in Phase 1 Designs

Posted on digi By digi

Phase 1 clinical trials primarily focus on safety, pharmacokinetics (PK), and tolerability in healthy volunteers or patients. While not always required, blinding and randomization can significantly enhance the scientific rigor and credibility of early-phase data—particularly when subjective assessments or placebo responses may affect interpretation. This tutorial explains the key considerations for applying blinding and randomization in Phase 1 study designs, including benefits, practical implementation, ethical issues, and regulatory expectations.
Click to read the full article.

Phase 1 (Safety and Dosage)

Safety Reporting to Regulators in Phase 4: Timelines and Format

Posted on digi By digi

As drugs transition from controlled trials to widespread real-world use, the scope of adverse event reporting broadens considerably. In Phase 4 clinical trials, sponsors are expected to comply with stringent global regulations concerning timelines, formats, and content for safety reporting. This includes spontaneous adverse event reports, periodic safety update reports (PSURs), and signal evaluations—often across multiple jurisdictions simultaneously.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Managing Investigator Turnover and Site Closures in Late-Stage Trials: Strategies for Continuity and Compliance

Posted on digi By digi

Phase 3 clinical trials often run for 2–5 years, involve hundreds of global sites, and are subject to evolving clinical, regulatory, and operational pressures. During this extended timeline, it’s common to encounter Principal Investigator (PI) turnover or even complete site closures. These disruptions can pose serious risks to data continuity, regulatory compliance, participant safety, and trial timelines.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Operational Risk Management in First-in-Human Studies

Posted on digi By digi

First-in-human (FIH) studies represent a pivotal milestone in drug development but also carry the highest degree of uncertainty and risk. These early-phase trials require precise operational planning, stringent safety monitoring, and proactive communication. Operational risk management in FIH trials is essential to protect participants, ensure data integrity, and enable efficient dose escalation decisions. This guide provides a practical framework for identifying, mitigating, and managing operational risks in FIH clinical trials.
Click to read the full article.

Phase 1 (Safety and Dosage)

Effectiveness Assessment in Subpopulations During Phase 4 Clinical Trials

Posted on digi By digi

Phase 4 clinical trials, conducted after regulatory approval, offer a unique opportunity to assess the real-world effectiveness of a drug. One of the most valuable aspects of this phase is evaluating how different subpopulations respond to the treatment. These could include variations based on age, gender, race, comorbidities, or genetic profiles. Identifying and understanding such differences is essential for achieving precision medicine and improving treatment outcomes across diverse patient groups.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Patient Retention Strategies in Long-Term Phase 3 Studies: Keeping Participants Engaged and Compliant

Posted on digi By digi

Long-term Phase 3 clinical trials can span months or even years, especially in therapeutic areas like oncology, cardiovascular disease, and rare disorders. During this extended timeline, patient retention becomes just as critical as recruitment. Each patient lost can disrupt statistical power, affect regulatory acceptability, and compromise the integrity of the study’s findings.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Phase 1 Trials in Rare Diseases: Study Design Constraints

Posted on digi By digi

Phase 1 clinical trials in rare diseases present a unique set of challenges. Unlike traditional early-phase studies that enroll healthy volunteers, trials for rare conditions often require patient participation from the outset. This is due to ethical considerations, unique pathophysiology, and lack of healthy correlates. With small, geographically dispersed populations and heterogeneous phenotypes, designing scientifically sound and ethically robust Phase 1 trials for rare diseases demands creativity, regulatory insight, and flexible design strategies.
Click to read the full article.

Phase 1 (Safety and Dosage)